-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – norovirus [strains GI.1 + GII.4] (bivalent, virus-like particle) vaccine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry norovirus [strains GI.1 + GII.4] (bivalent, virus-like particle) vaccine Drug Details Vaccine candidate is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine Drug Details The vaccine candidate...
-
Product Insights
Net Present Value Model: TAK-214
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TAK-214 Drug Details HIL-214 was under...
-
Product Insights
Net Present Value Model: HIL-214
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model HIL-214 Drug Details HIL-214 was under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HIL-214
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry HIL-214 Drug Details HIL-214 was under development for the prevention of acute gastroenteritis caused...
-
Product Insights
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis – Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape. Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis – Drugs In...